collection
MENU ▼
Read by QxMD icon Read
search

Mama

shared collection
48 papers 25 to 100 followers
By Alessandro Franciscon doctor
https://www.readbyqxmd.com/read/28898379/effect-of-axillary-dissection-vs-no-axillary-dissection-on-10-year-overall-survival-among-women-with-invasive-breast-cancer-and-sentinel-node-metastasis-the-acosog-z0011-alliance-randomized-clinical-trial
#1
RANDOMIZED CONTROLLED TRIAL
Armando E Giuliano, Karla V Ballman, Linda McCall, Peter D Beitsch, Meghan B Brennan, Pond R Kelemen, David W Ollila, Nora M Hansen, Pat W Whitworth, Peter W Blumencranz, A Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow
Importance: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years. Longer follow-up was necessary because the majority of the patients had estrogen receptor-positive tumors that may recur later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology). Objective: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary dissection...
September 12, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28943046/radical-radiation-therapy-for-oligometastatic-breast-cancer-results-of-a-prospective-phase-ii-trial
#2
Marco Trovo, Carlo Furlan, Jerry Polesel, Francesco Fiorica, Stefano Arcangeli, Niccolò Giaj-Levra, Filippo Alongi, Alessandro Del Conte, Loredana Militello, Elena Muraro, Debora Martorelli, Simon Spazzapan, Massimiliano Berretta
BACKGROUND AND PURPOSE: We conducted a prospective phase II multicentric trial to determine if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. Secondary endpoints were local control (LC), overall survival (OS) and toxicity. METHODS AND MATERIALS: Inclusion criteria were the following: oligometastatic breast cancer with ≤5 metastatic sites, FDG-PET/CT staging, no brain metastases, primary tumor controlled...
September 21, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28822332/eso-esmo-3rd-international-consensus-guidelines-for-breast-cancer-in-young-women-bcy3
#3
Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, Omalkhair Abulkhair, Maria-João Cardoso, Rebecca Alexandra Dent, Karen Gelmon, Oreste Gentilini, Nadia Harbeck, Anita Margulies, Dror Meirow, Giancarlo Pruneri, Elzbieta Senkus, Tanja Spanic, Medha Sutliff, Luzia Travado, Fedro Peccatori, Fatima Cardoso
The 3rd International Consensus Conference for Breast Cancer in Young Women (BCY3) took place in November 2016, in Lugano, Switzerland organized by the European School of Oncology (ESO) and the European Society of Medical Oncologists (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY2 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA)...
October 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28391871/tamoxifen-with-radiotherapy-compared-with-tamoxifen-alone-in-elderly-women-with-early-stage-breast-cancer-treated-with-breast-conserving-surgery-a-systematic-review-and-meta-analysis
#4
REVIEW
Tyler R Chesney, Jennifer Xin Yin, Nikoo Rajaee, Andrea C Tricco, Anthony W Fyles, Sergio A Acuna, Adena S Scheer
BACKGROUND: Our aim was to assess the effect of adjuvant radiotherapy on recurrence and survival for elderly women (≥70) with early-stage hormone receptor-positive breast cancer treated with breast conserving surgery (BCS) and Tamoxifen. MATERIALS AND METHODS: MEDLINE, EMBASE, and Evidence-Based Medicine Reviews were systematically searched through August 12, 2016 for randomized controlled trials (RCTs) comparing radiotherapy to no radiotherapy and presenting outcomes for women ≥70years...
April 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28382401/management-of-the-positive-axilla-in-2017
#5
EDITORIAL
Eli Avisar, Tolga Ozmen
No abstract text is available yet for this article.
June 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/23032615/predictors-of-locoregional-recurrence-after-neoadjuvant-chemotherapy-results-from-combined-analysis-of-national-surgical-adjuvant-breast-and-bowel-project-b-18-and-b-27
#6
Eleftherios P Mamounas, Stewart J Anderson, James J Dignam, Harry D Bear, Thomas B Julian, Charles E Geyer, Alphonse Taghian, D Lawrence Wickerham, Norman Wolmark
PURPOSE: The limited information on predictors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph node biopsy. PATIENTS AND METHODS: We examined patterns and predictors of LRR as first event in combined analysis of two National Surgical Adjuvant Breast and Bowel Project (NSABP) neoadjuvant trials. NC was either doxorubicin/cyclophosphamide (AC) alone or AC followed by neoadjuvant/adjuvant docetaxel...
November 10, 2012: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/11773149/predictors-of-local-regional-recurrence-after-neoadjuvant-chemotherapy-and-mastectomy-without-radiation
#7
Thomas A Buchholz, Susan L Tucker, Lawrence Masullo, Henry M Kuerer, Jessica Erwin, Jessica Salas, Debbie Frye, Eric A Strom, Marsha D McNeese, George Perkins, Angela Katz, S Eva Singletary, Kelly K Hunt, Aman U Buzdar, Gabriel N Hortobagyi
PURPOSE: To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant chemotherapy and mastectomy without radiation. PATIENTS AND METHODS: We analyzed the outcome of the 150 breast cancer cases treated on prospective institutional trials with neoadjuvant chemotherapy and mastectomy without postmastectomy radiation. Clinical stage at diagnosis was I in 1%, II in 43%, IIIA in 23%, IIIB in 25%, and IV in 7%. No patient had inflammatory breast cancer...
January 1, 2002: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/10924981/is-radiation-alone-adequate-treatment-to-the-axilla-for-patients-with-limited-axillary-surgery-implications-for-treatment-after-a-positive-sentinel-node-biopsy
#8
S Galper, A Recht, B Silver, M V Bernardo, R Gelman, J Wong, S J Schnitt, J L Connolly, J R Harris
PURPOSE: To estimate the possible efficacy of axillary radiation therapy (AXRT) following a positive sentinel node biopsy (SNB), we evaluated the risk of regional nodal failure (RNF) for patients with clinical Stage I or II, clinically node-negative invasive breast cancer treated with either no dissection or a limited dissection (LD) defined as removal of 5 nodes or less followed by AXRT. MATERIALS AND METHODS: From 1978 to 1987, 292 patients underwent AXRT in the absence of axillary dissection; 126 underwent AXRT following LD...
August 1, 2000: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/23690420/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or-older-with-early-breast-cancer-long-term-follow-up-of-calgb-9343
#9
RANDOMIZED CONTROLLED TRIAL
Kevin S Hughes, Lauren A Schnaper, Jennifer R Bellon, Constance T Cirrincione, Donald A Berry, Beryl McCormick, Hyman B Muss, Barbara L Smith, Clifford A Hudis, Eric P Winer, William C Wood
PURPOSE: To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. PATIENTS AND METHODS: Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women)...
July 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21900114/age-breast-cancer-subtype-approximation-and-local-recurrence-after-breast-conserving-therapy
#10
Nils D Arvold, Alphonse G Taghian, Andrzej Niemierko, Rita F Abi Raad, Meera Sreedhara, Paul L Nguyen, Jennifer R Bellon, Julia S Wong, Barbara L Smith, Jay R Harris
PURPOSE: Prior results of breast-conserving therapy (BCT) have shown substantial rates of local recurrence (LR) in young patients with breast cancer (BC). PATIENTS AND METHODS: We studied 1,434 consecutive patients with invasive BC who received BCT from December 1997 to July 2006. Ninety-one percent received adjuvant systemic therapy; no patients received trastuzumab. Five BC subtypes were approximated: estrogen receptor (ER) or progesterone receptor (PR) positive, HER2 negative, and grades 1 to 2 (ie, luminal A); ER positive or PR positive, HER2 negative, and grade 3 (ie, luminal B); ER or PR positive, and HER2 positive (ie, luminal HER2); ER negative, PR negative, and HER2 positive (ie, HER2); and ER negative, PR negative, and HER2 negative (ie, triple negative)...
October 10, 2011: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27919884/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3
#11
F Cardoso, A Costa, E Senkus, M Aapro, F André, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, A Gennari, N Harbeck, C Hudis, B Kaufman, I Krop, M Mayer, H Meijer, S Mertz, S Ohno, O Pagani, E Papadopoulos, F Peccatori, F Pernault-Llorca, M J Piccart, J Y Pierga, H Rugo, L Shockney, G Sledge, S Swain, C Thomssen, A Tutt, D Vorobiof, B Xu, L Norton, E Winer
No abstract text is available yet for this article.
December 5, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27646947/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update
#12
REVIEW
Abram Recht, Elizabeth A Comen, Richard E Fine, Gini F Fleming, Patricia H Hardenbergh, Alice Y Ho, Clifford A Hudis, E Shelley Hwang, Jeffrey J Kirshner, Monica Morrow, Kilian E Salerno, George W Sledge, Lawrence J Solin, Patricia A Spears, Timothy J Whelan, Mark R Somerfield, Stephen B Edge
Purpose A joint American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology panel convened to develop a focused update of the American Society of Clinical Oncology guideline concerning use of postmastectomy radiotherapy (PMRT). Methods A recent systematic literature review by Cancer Care Ontario provided the primary evidentiary basis. The joint panel also reviewed targeted literature searches to identify new, potentially practice-changing data. Recommendations The panel unanimously agreed that available evidence shows that PMRT reduces the risks of locoregional failure (LRF), any recurrence, and breast cancer mortality for patients with T1-2 breast cancer with one to three positive axillary nodes...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21852010/adjuvant-chemotherapy-and-radiotherapy-in-triple-negative-breast-carcinoma-a-prospective-randomized-controlled-multi-center-trial
#13
RANDOMIZED CONTROLLED TRIAL
Jianhua Wang, Mei Shi, Rui Ling, Yuesheng Xia, Shanquan Luo, Xuehai Fu, Feng Xiao, Jianping Li, Xiaoli Long, Jianguo Wang, Zengxia Hou, Yunxia Chen, Bin Zhou, Man Xu
BACKGROUND AND PURPOSE: Triple-negative breast cancer (TNBC) presents a high risk breast cancer that lacks the benefit from hormone treatment, chemotherapy is the main strategy even though it exists in poor prognosis. Use of adjuvant radiation therapy, which significantly decreases breast cancer mortality, has not been well described among poor TNBC women. The aim of this study was to evaluate whether the combination of chemotherapy and radiotherapy could significantly increase survival outcomes in TNBC women after mastectomy...
August 2011: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/15850919/patient-subsets-with-t1-t2-node-negative-breast-cancer-at-high-locoregional-recurrence-risk-after-mastectomy
#14
Pauline T Truong, Mary Lesperance, Aydin Culhaci, Hosam A Kader, Caroline H Speers, Ivo A Olivotto
PURPOSE: To identify patient subsets with T1-T2N0 breast cancer at high risk of locoregional recurrence (LRR) who may warrant consideration for postmastectomy radiotherapy. METHODS AND MATERIALS: Data were analyzed for 1505 women referred between 1989 and 1999 with pathologic T1-T2N0M0 breast cancer treated with mastectomy with clear margins and no adjuvant radiotherapy. Logistic regression analysis was performed to identify statistically significant factors associated with LRR...
May 1, 2005: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/17577015/impact-of-a-higher-radiation-dose-on-local-control-and-survival-in-breast-conserving-therapy-of-early-breast-cancer-10-year-results-of-the-randomized-boost-versus-no-boost-eortc-22881-10882-trial
#15
RANDOMIZED CONTROLLED TRIAL
Harry Bartelink, Jean-Claude Horiot, Philip M Poortmans, Henk Struikmans, Walter Van den Bogaert, Alain Fourquet, Jos J Jager, Willem J Hoogenraad, S Bing Oei, Carla C Wárlám-Rodenhuis, Marianne Pierart, Laurence Collette
PURPOSE: To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fibrosis, and overall survival for patients with stage I and II breast cancer who underwent breast-conserving therapy. PATIENTS AND METHODS: A total of 5,318 patients with microscopically complete excision followed by whole-breast irradiation of 50 Gy were randomly assigned to receive either a boost dose of 16 Gy (2,661 patients) or no boost dose (2,657 patients), with a median follow-up of 10...
August 1, 2007: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21134654/intensity-modulated-radiation-therapy-for-breast-is-it-for-everyone
#16
REVIEW
Beryl McCormick, Margie Hunt
Intensity-modulated radiation therapy (IMRT) became available to the radiation oncology community in the late 1990s, and its initial applications were to increase conformality of dose to the target, allowing for both dose escalation and decreased radiation to adjacent normal organs. In most disease sites, these continue to be the goals of IMRT. However, for breast cancer, IMRT has emerged with a different endpoint, namely improving dose homogeneity throughout the targeted breast. In 2 recent prospective randomized trials comparing IMRT with "standard" planning, IMRT was associated with a significant decrease in both acute side effects and late fibrosis, which was related directly to dose homogeneity...
January 2011: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/26604820/hypofractionated-whole-breast-radiotherapy-current-perspectives
#17
REVIEW
Theodora A Koulis, Tien Phan, Ivo A Olivotto
Adjuvant radiotherapy (RT) is an important part of breast cancer management but the dose and fractionation schedules used are variable. A total of 50 Gy in 25 daily fractions delivered over 5 weeks is often considered the "standard" adjuvant RT prescription. Hypofractionated regimes such as 42.5 Gy in 16 daily fractions or 40 Gy in 15 daily fractions following breast-conserving surgery have proven to be equally effective and achieve similar or better cosmetic and normal tissue outcomes for both invasive and in situ diseases and when treating the regional nodes...
2015: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/18922117/trial-assessing-individualized-options-for-treatment-for-breast-cancer-the-tailorx-trial
#18
RANDOMIZED CONTROLLED TRIAL
Jo Anne Zujewski, Leah Kamin
Novel genetic profiling tests of breast cancer tissue have been shown to be prognostic for overall survival and predictive of local and distant rates of recurrence in breast cancer patients. One of these tests, Oncotype DXtrade mark, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome...
October 2008: Future Oncology
https://www.readbyqxmd.com/read/26617212/contemporary-breast-radiotherapy-and-cardiac-toxicity
#19
REVIEW
Debra Nana Yeboa, Suzanne Buckley Evans
Long-term cardiac effects are an important component of survivorship after breast radiotherapy. The pathophysiology of cardiotoxicity, history of breast radiotherapy, current methods of cardiac avoidance, modern outcomes, context of historical outcomes, quantifying cardiac effects, and future directions are reviewed in this article. Radiation-induced oxidative stress induces proinflammatory cytokines and is a process that potentiates late effects of fibrosis and intimal proliferation in endothelial vasculature...
January 2016: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/26768026/phyllodes-tumours-of-the-breast-a-consensus-review
#20
REVIEW
Benjamin Y Tan, Geza Acs, Sophia K Apple, Sunil Badve, Ira J Bleiweiss, Edi Brogi, José P Calvo, David J Dabbs, Ian O Ellis, Vincenzo Eusebi, Gelareh Farshid, Stephen B Fox, Shu Ichihara, Sunil R Lakhani, Emad A Rakha, Jorge S Reis-Filho, Andrea L Richardson, Aysegul Sahin, Fernando C Schmitt, Stuart J Schnitt, Kalliopi P Siziopikou, Fernando A Soares, Gary M Tse, Anne Vincent-Salomon, Puay Hoon Tan
Phyllodes tumours constitute an uncommon but complex group of mammary fibroepithelial lesions. Accurate and reproducible grading of these tumours has long been challenging, owing to the need to assess multiple stratified histological parameters, which may be weighted differently by individual pathologists. Distinction of benign phyllodes tumours from cellular fibroadenomas is fraught with difficulty, due to overlapping microscopic features. Similarly, separation of the malignant phyllodes tumour from spindle cell metaplastic carcinoma and primary breast sarcoma can be problematic...
January 2016: Histopathology
label_collection
label_collection
3610
1
2
2016-02-03 13:36:02
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"